hotspot -WSS

hotspot

author：comprehensive 2025-09-29 17:52:51 - browse：3

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Software glitch causes Tandem insulin pump to shutdown, FDA warns

WSS

The health care issue Democrats can’t solve: hospital reform

Use wet bulb globe temperature, not heat index, to protect workers

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Gene therapy’s promise and the high cost of hope

Inari Medical to buy amputation prevention company LimFlow

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Gene therapy’s promise and the high cost of hope

United colonoscopy coverage change 'may cost lives,' doctors say

Travis Kelce and the trap of celebrity vaccine endorsements

Hepatitis C has a cure — but many Americans still lack access to it

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Apple is now the first public company to be valued at $3 trillion

Inari Medical to buy amputation prevention company LimFlow

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sarepta Duchenne therapy fails to meet primary endpoint in trial

explore

What nurses really want: sufficient staffing for patient care

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

All of Us, NIH's precision medicine initiative, gets a big boost

Bill would allow buprenorphine prescription for addiction via telehealth

Study: AI not yet building 'n

Steward Health Care files for bankruptcy

Wikipedia

hotspot

hotspot

Wikipedia